Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2015-03, Vol.29 (3), p.744-747
Hauptverfasser:	Pepper, C, Buggins, A G S, Jones, C H, Walsby, E J, Forconi, F, Pratt, G, Devereux, S, Stevenson, F K, Fegan, C
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/106 13/31 692/308 692/499 Agammaglobulinaemia Tyrosine Kinase Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Cancer Research Chemokine CXCL12 - genetics Chemokine CXCL12 - metabolism Chronic lymphocytic leukemia Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors Class I Phosphatidylinositol 3-Kinases - genetics Class I Phosphatidylinositol 3-Kinases - metabolism Critical Care Medicine Gene Expression Regulation, Neoplastic Genetic aspects Genetic Heterogeneity Hematology Heterocyclic Compounds - therapeutic use Humans Identification and classification Immunoglobulin Heavy Chains - genetics Immunoglobulin Heavy Chains - metabolism Integrin alpha4 - genetics Integrin alpha4 - metabolism Intensive Internal Medicine Letter to the Editor Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemia, Lymphocytic, Chronic, B-Cell - pathology Medicine Medicine & Public Health Mutation Natalizumab Oncology Phenotype Prognosis Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Purines - therapeutic use Pyrazoles - therapeutic use Pyrimidines - therapeutic use Quinazolinones - therapeutic use Receptors, CXCR4 - antagonists & inhibitors Receptors, CXCR4 - genetics Receptors, CXCR4 - metabolism Signal Transduction Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2014.308